Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-25 @ 3:21 AM
NCT ID:
NCT01927705
Eligibility Criteria:
Inclusion Criteria:
* Of either gender, aged ≥20 and ≤60 years
* Atopic Dermatitis subjects who are coincident with Hanifin and Rajka diagnosis criteria
* subacute and chronic Atopic subjects who have Atopic Dermatitis symptoms continually at least 6 months
* Subjects with over moderate atopic dermatitis( SCORAD score \> 20 )
* Subjects who understand and voluntarily sign an informed consent form
Exclusion Criteria:
* Subjects who have systemic infection at the baseline visit
* Subjects who have asthma at the baseline visit
* Treatment with oral corticosteroids, oral antibiotics, whole body photochemotherapy, immunosuppressive drug within 4 weeks before the baseline visit
* Treatment with topical steroids, antibiotics within 2 weeks before the baseline visit
* Subjects who already took or need to take the medicine which is prohibited to take during the clinical study.
* Pregnant, breast-feeding women or women who plan to become pregnant during this study. (Females of Childbearing Potential must have a negative urine pregnancy test at Screening and Baseline)
* Subjects who currently participate in other clinical trial or participated in other clinical trial within 30 days
* Creatinine value ≥ 2 Upper limit of the normal range at screening test
* AST/ALT value ≥ 2 Upper limit of the normal range at screening test
* Any other condition which the investigator judges would make patient unsuitable for study participation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
60 Years
Study:
NCT01927705
Study Brief:
Protocol Section:
NCT01927705